← Eichor
Study identifier: NCT05762900 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Ultra-hypofractioNated Adjuvant Radiotherapy ± sImultaneous Integrated Boost for Low-risk Breast Cancer Patients

Condition: Breast Cancer · Radiotherapy Side Effect  ·  Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

PhasePhase 2
Planned participants65
Who can joinFemale, 35 Years to no upper limit
Healthy volunteersNo

About this study

This is a phase II study to investigate the feasibility of Ultra-hypofractionated radiotherapy with or without simultaneous integrated boost for low risk breast cancer patients who have received breast conservative surgery of mastectomy.

This description comes directly from the study's public registry record.

Talk to the study team

Shu-Lian Wang, M.D.  ·  8610-87788290  ·  wangsl@cicams.ac.cn

Always discuss trial participation with your own doctor first.

Locations (1)

National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05762900